G6PD and hepatocellular carcinoma: This study uncovers the therapeutic mechanism of RRx-001 in hepatocellular carcinoma (HCC): by inhibiting G6PD, it reduces NADPH levels, leading to redox imbalance and F-actin contraction, thereby inducing disulfidptosis-a process that can be partially reversed by TCEP.